1[1]Macleod MJ, Melay J. Drug treatment of hypertension.Complicating diabetes mellitus. Drugs 1998; 56:189 ～ 202. 被引量：1
2[2]UKPDS Group: Tight blood pressure control and risk of macrovascular, and microvasoular complicatons in type 2 diabetes (UKPDS38). BMJ 1998;317:703～704. 被引量：1
3[3]Patrick J, Mulrow MD. News form the world hypertension league. A division of th e international society of hypertension, and in official relations with the WHO. WHL. Newsletter 2000; No.71. 被引量：1
4[4]Christlieb AR. Treatment selection considerations for the hypertensive diabetic patient. Arch Intern Med 1990;150:1167～ 1174. 被引量：1
5[5]Good JM, Brady AJ, Ncormohamed FH, et al. Effect of intense angiotension Ⅱ suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation 1994.90:220 ～ 224. 被引量：1
6[6]Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diruetic for the treatment of hypertension.Arch Intern Med. 1990; 150:1175～ 1183. 被引量：1
7[7]Pahor M, Tatti P. The Fosinopril versus Amlodipine Cardovascular Events Trial(FACET)and combination therapies. Am J Cardiol 1990;83:819～820. 被引量：1
8[8]Scheen AT, Chinical study of the month. The CAPPP study:The captopril prevention project. Rev Med Liege 1999;54 : 197～ 199. 被引量：1
9[1]Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection,evaluation, and treatment of high blood pressure. J AMA,2003, 289: 2560-2572. 被引量：1
10[2]2003 European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens, 2003, 21: 1011-1053. 被引量：1
